Olokizumab vs placebo or usual care
All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether olokizumab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).
1 finding from 1 review
- Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes onlyRR 1.5 [0.55, 4.09]1 study · 248 participantsVery low